A Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Clinical Response After 4-week Oral Treatment With SAR441566 Compared With Placebo in Participants With Mild to Moderate Psoriasis
Latest Information Update: 03 Jan 2024
At a glance
- Drugs SAR 441566 (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- Sponsors Sanofi
- 15 Nov 2023 Results reporting safety and efficacy data over week 4 presented at the ACR Convergence 2023
- 14 Feb 2023 Status changed from recruiting to completed.
- 09 Aug 2021 New trial record